The "Dogs of the Dow†strategy has staged a comeback, and Kevin Simpson of Capital Wealth Planning believes 2026 could be another strong year. After a 17% gain in 2025, beating the broader Dow's perfo... ...

Argus Research将安进的目标价从310美元上调至360美元。 ...

Financial Performance - Amgen's revenue increased by 12% year-over-year to $9.6 billion in the third quarter, driven by strong sales from key products [2] - Repatha, a cholesterol treatment, generated $794 million in sales, marking a 40% increase from the previous year [2] - Tezspire, an asthma therapy, also saw revenue rise by 40% year-over-year to $377 million [2] Pipeline and Growth Prospects - The company may face growth challenges in the coming quarters due to biosimilar competition for denosumab, marketed as Prolia and Xgeva [3] - Despite potential pressures, Amgen has multiple avenues to mitigate impacts, including existing products with years of sales growth potential and an active pipeline [3] - MariTide, an investigational treatment for weight management, has advanced to phase 3 studies for obesity, type 2 diabetes, and other conditions [3] Dividend Outlook - Amgen has consistently raised its dividend since 2011, with a current forward yield of approximately 3%, significantly higher than the S&P 500 average of about 1.2% [4] - The company's cash payout ratio is near 46%, indicating potential for further dividend increases [4]

Core Insights - Bristol Myers Squibb (BMY) and Amgen (AMGN) are leading global biotechnology companies with diverse portfolios focused on various therapeutic areas [1][2] - Both companies have established strong market positions and consistently delivered shareholder value, making stock selection challenging [3] BMY Overview - BMY's growth portfolio includes drugs such as Opdivo, Reblozyl, and Breyanzi, contributing to strong top-line growth [4][10] - Opdivo sales are driven by its launch in MSI-high colorectal cancer and growth in non-small cell lung cancer, with global sales expected to increase in the high single-digit to low double-digit range by 2025 [5][6] - Reblozyl has annualized sales exceeding $2 billion, significantly boosting BMY's revenue, while Breyanzi sales are also strong, annualizing over $1 billion [7][8] - BMY's legacy portfolio is facing challenges due to generic competition, with expected declines of 15-17% in 2025 [11][12] AMGN Overview - Amgen has a vast portfolio with strong positions in oncology, cardiovascular disease, and rare diseases, supported by growth products like Repatha and Tezspire [13][14] - Despite competitive pressures affecting some products, Amgen's growth trajectory is driven by key drugs and a robust pipeline [15] - The acquisition of Horizon Therapeutics has expanded Amgen's rare disease offerings, enhancing its market position [16] Financial Estimates - BMY's 2025 sales are estimated to decrease by 0.8%, while EPS is expected to increase by 466.09% [17] - AMGN's 2025 sales are projected to grow by 8.78%, with EPS improving by 7.26% [20] Price Performance and Valuation - Over the past six months, BMY has outperformed AMGN slightly, with gains of 13.9% compared to AMGN's 13.5% [21] - In terms of valuation, AMGN trades at a higher forward P/E of 15.2X compared to BMY's 8.99X, indicating a more expensive valuation [21] - BMY offers a higher dividend yield of 4.54% compared to AMGN's 2.86% [22] Investment Considerations - Both companies are considered safe investments in the biotech sector, but AMGN is currently viewed as a better pick due to solid fundamentals and positive estimate revisions [23][25]

Core Insights - Amgen is developing MariTide, a late-stage obesity candidate, to compete with Eli Lilly and Novo Nordisk in the GLP-1 therapy market [1] - MariTide's long-acting profile allows for monthly or less frequent dosing, potentially improving patient adherence compared to weekly injectable options [2] - The drug is being evaluated in pivotal studies for obesity and other cardiometabolic conditions, with strong enrollment interest [3][4] Group 1: Product Development and Market Position - MariTide is part of Amgen's MARITIME phase III program, focusing on obesity and related cardiometabolic indications [1][3] - The drug has shown predictable and sustained weight loss in earlier studies, positioning it as a convenient long-term treatment option [2] - Enrollment for MARITIME-1 and MARITIME-2 studies has been completed with approximately 5,000 patients participating [3] Group 2: Competitive Landscape - Novo Nordisk has received FDA approval for an oral version of Wegovy, enhancing competition in the obesity treatment market [5] - Eli Lilly is also advancing its oral obesity candidate, orforglipron, with a potential launch next year [6] - Both market leaders continue to invest in next-generation therapies, indicating a robust competitive environment [7][8] Group 3: Financial Performance and Valuation - Amgen's shares have outperformed the industry year to date, reflecting positive market sentiment [9] - The company is trading at a P/E ratio of 15.20, which is below the industry average of 17.56, indicating a potential valuation opportunity [12] - EPS estimates for 2025 and 2026 have increased in the past 60 days, suggesting positive growth expectations [14]

In this article, we will take a look at some of the best dividend stocks.Drug pricing has become one of the biggest pressure points for pharmaceutical companies this year, as the U.S. moves to rein in what consumers pay at the pharmacy counter.For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other developed countries. Branded medicines carry even steeper premiums. That gap explains why so much of the industry’s revenue still depends on Amer ...

Summary of Key Points from the Conference Call Industry Overview - **Industry**: Biopharma in North America - **Market Analysis**: The latest weekly Total Prescription (TRx) year-over-year (YoY) growth for the week ending December 19, 2025, was +1.1%, compared to +1.0% the previous week and +0.8% over the past 12 weeks [1][2] Prescription Trends - **Weekly TRx Change**: For the week ended December 19, the US total market weekly TRx YoY change was +1.1%, up from +0.9% a year ago. The rolling 4-week TRx YoY was +1.2%, and the rolling 12-week TRx YoY was +0.8% [2] - **Extended Unit (EUTRx) Growth**: EUTRx weekly YoY growth was +1.4%, which is above the TRx YoY growth [2] - **Sequential Growth**: Sequential weekly TRx growth was +2.3%, a significant increase compared to -1.4% the week before [2] Company-Specific Insights Bristol Myers Squibb (BMY) - **Cobenfy Launch**: Cobenfy was approved for schizophrenia on September 26, 2024. The number of prescriptions (scripts) for the week was approximately 2,800, up from 2,710 the previous week. To meet 2025 consensus expectations, Cobenfy TRx needs to track at approximately 2-3 times the volumes from recent schizophrenia launches [3] - **Sales Estimates**: The consensus estimate for Cobenfy has decreased from $196 million to $161 million, implying that around 104,000 TRx are required to meet these estimates [3] Vertex Pharmaceuticals (VRTX) - **Journavx Launch**: Journavx was approved for acute pain on January 30, 2025. The number of scripts for the week was approximately 13,060, up from 12,570 the previous week. Hospital scripts accounted for about 39% of total scripts in Q3 [4] - **Sales Projections**: To achieve 2025 sales of $68 million, approximately 303,000 total scripts are needed, assuming a net price of $225 per script [4] Gilead Sciences (GILD) - **Yeztugo Launch**: Yeztugo was approved on June 18, 2025. The latest week total TRx was approximately 780, down from 800 the previous week. The analysis suggests that achieving FY25 sales of $150 million requires incremental weekly script growth from current levels [5][9] - **Market Coverage**: Yeztugo has secured 75% commercial coverage, including major payers, and most do not require copays, indicating alignment with USPSTF guidelines [9] Additional Insights - **Market Focus**: Investors are increasingly focused on 2026, with strong PrEP market growth of +14% YoY and sustained Descovy share of over 45% [9] - **Pricing Analysis**: The pricing analysis for immunology drugs such as Stelara and Tremfya has been updated, showing how additional indications impact price per script [10] - **Biosimilar Adoption**: Comprehensive analysis of biosimilar adoption across various branded drugs has been included, indicating trends in market share and sales [12] Conclusion - The biopharma industry in North America is showing positive growth trends in total prescriptions, with specific companies like BMY, VRTX, and GILD launching new products and adjusting sales expectations. The focus on 2026 and the strong market coverage for new drugs indicate potential investment opportunities in this sector.

With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commitment to delivering substantial returns and strategic insights to its clients. In a world filled with complexities, Allka Re ...

With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commitment to delivering substantial returns and strategic insights to its clients. In a world filled with complexities, Allka Re ...

Key Takeaways AMGN agreed to lower U.S. drug prices, align them with other developed markets and offer deep DTC discounts.AMGN expanded its AmgenNow program to Repatha, Aimovig and Amjevita with discounts of up to 80%.Amgen plans $2.5B in U.S. manufacturing and R&D investments tied to tariff exemptions.Amgen (AMGN) recently signed a landmark agreement with the Trump administration to lower drug prices in the United States.Through this deal, Amgen addresses the two major concerns that have plagued Big Pharma ...